Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten
Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate ... Read More
AstraZeneca gets FDA breakthrough status for Farxiga in CKD
AstraZeneca has been granted breakthrough therapy designation (BTD) for Farxiga (dapagliflozin) from the US Food and Drug Administration (FDA) for the treatment of patients with ... Read More
Kyowa Kirin gets extended EC approval for CRYSVITA in X-linked hypophosphataemia
Kyowa Kirin has secured extended approval for CRYSVITA (burosumab) from the European Commission (EC) in X-linked hypophosphataemia (XLH), to cover the treatment of older adolescents ... Read More
FDA approves BMS’ Opdivo, Yervoy combo for malignant pleural mesothelioma
Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line ... Read More
Novartis reports positive results for Aimovig in phase 2 episodic migraine trial
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients ... Read More
Dr. Reddy’s launches Sapropterin Dihydrochloride Tablets generic version in US
Indian pharma company Dr. Reddy’s Laboratories has launched a generic version of phenylalanine hydroxylase activator Sapropterin Dihydrochloride Tablets, for oral use, in the US market. ... Read More
Covis Group to acquire US biopharma company AMAG Pharmaceuticals
Covis Group, a Luxembourg specialty pharma company, has agreed to acquire US biopharma company AMAG Pharmaceuticals for about $647 million, which includes the latter’s debt. ... Read More
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer
US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological ... Read More
Chinese biotech company InventisBio raises $147m in Series D round
InventisBio, a Chinese biotech company focused on small molecule drugs, has raised $147 million in a Series D funding round. The funding round of the ... Read More
XtalPi raises $319m for AI based drug research and development
XtalPi, a pharma company that leverages artificial intelligence (AI) for drug discovery and development, has raised $318.8 million in a Series C round. The funding ... Read More